Biogen stock rips higher on a promising new drug. Here's what Wall Street is saying.
Threadneedle Street will now start buying bonds to stabilise what it described as 'dysfunctional markets'.
Things are bad. But at least ‘you can eat’ one of these assets.
The benchmark S&P 500, which is typically viewed as the best barometer of stock market health, produced its worst first-half return in 52 years. As for the growth-driven Nasdaq Composite, an index largely responsible for pushing the stock market to new highs, it's lost about a third of its value. This puts both the S&P 500 and Nasdaq firmly in a bear market.
The CBOE Volatility Index has skyrocketed 89% so far this year. Morningstar put together a list of stocks with one- and three-year betas of 0.8 or lower. Then it screened for stocks that are undervalued, according to Morningstar analysts' fair value estimates.
(Bloomberg) -- As crazy as it sounds, all the turmoil that’s ripped through Wall Street over the past week has still left debt markets in Corporate America relatively unscathed.Most Read from BloombergGermany Suspects Sabotage Hit Russia’s Nord Stream PipelinesPutin’s Mobilization Hits Russia’s Economy in Its Weak SpotsAlzheimer’s Progression Slowed by Drug in Major TrialUS Housing Prices Fall for First Time Since 2012Everything-Selloff on Wall Street Deepens on 98% Recession OddsThat’s bad news
(Reuters) -Shares in Biogen Inc and Japanese partner Eisai skyrocketed on Wednesday, as a surprise trial success of their experimental Alzheimer's drug was hailed as an unequivocal win by Wall Street analysts. The trial results released on late Tuesday could mark a rare victory in the search for a treatment for the memory-robbing disease after years of clinical failures. Biogen's stock surged 46.6% to $290.99 in premarket trading, putting it on track to add over $13.5 billion in market capitalization.
Anyone following stock market trends in 2022 will be well aware of the widespread drawbacks; apart from some outliers such as energy, most corners of the market have been beaten to a pulp. The main culprits are easily identified by now; a combination of a slowing economy, rampant inflation, rates hikes to halt it, and Russia’s invasion of Ukraine and the global implications are all responsible factors. Stock market giants have not been immune either and many have seen huge chunks of their valuat
The stock market doesn't care what your cost basis is. NVIDIA (NASDAQ: NVDA) and Advanced Micro Devices (NASDAQ: AMD), two semiconductor stocks that were soaring until late 2021, have seen much of those gains come undone as chip shortages have given way to chip gluts. Both NVIDIA and AMD were doing well before the pandemic hit.
In this article, we discuss 10 most shorted stocks in the world. If you want to see more stocks on this list, click 5 Most Shorted Stocks in the World. Short squeezes have rapidly gained popularity in the last two years, when retail investors on Reddit gathered to initiate bullish positions in stocks that were […]
Apple is curbing iPhone production. The 10-year yield hit 4%, until the Bank of England stepped in. A Biogen Alzheimer's drug shows promise.
The Federal Reserve will hike its key interest rate to a much higher peak than predicted two weeks ago and the risks are skewed towards an even higher terminal rate, according to economists polled by Reuters. That change in expectations came after the Fed raised rates by 75 basis points last week for the third straight meeting and foresaw going higher than it had previously thought to tame inflation, which is running over four times above target. Since then, already battered global stocks went much deeper into bear market territory - a decline of 20% or more - on fears of recession and most currencies weakened further against the multi-decade high dollar.
Shares of Eli Lilly (NYSE: LLY) recently ticked higher in response to encouraging words from a Wall Street analyst who follows the pharmaceutical industry. Colin Bristow at UBS, an investment bank, thinks this is the most attractive pharma stock you can buy right now. Is Bristow right about Eli Lilly?
These rock-solid income stocks, with yields ranging from 7.8% to 13.8%, are perfectly positioned to make patient investors richer.
As a case in point, Buffett owns more stocks than you'll find listed in Berkshire Hathaway's (NYSE: BRK.A) (NYSE: BRK.B) regulatory filings. You might even say that Buffett has a "secret portfolio." Berkshire's acquisition of General Re years ago brought New England Asset Management (NEAM) into its fold.
Barring selected periods of relief, the inherent trend of the stock market has been resolutely negative in 2022. For investors searching for ways to boost the portfolio’s performance, there have generally been slim pickings. But if you look on the bright side of a market situation where stocks are continuously pushed further down, what you get are some low and enticing entry points. Roth Capital’s tech and communications expert Scott Searle certainly thinks that with a bit of digging, investors
Medicare beneficiaries will see their Part B premiums go down for the first time in more than a decade, President Biden said during a press conference on Tuesday. Monthly Part B premiums, which are currently set at $170.10 in 2022, will decline to $164.90 in 2023 – a $5.20 a month savings, or about $64 a year, according to the Centers for Medicare and Medicaid Services. The annual deductible for Part B will be $226, down $7 from $233 in 2022.
Shares of Apple suppliers STMicro and Taiwan Semiconductor fall on a report the tech giant is scrapping plans to increase iPhone production following weaker-than-expected demand.
The 86-year-old investing legend has spoken. Pay attention.
When AT&T updated its corporate strategy, it decided to sell off its entertainment properties, which was a smart move